Juvenile idiopathic arthritis, older age, and concomitant immunomodulation delay the onset of psoriasiform dermatitis in ...

So let’s get into it. Here’s everything you need to know to address uncommon UC symptoms and seize back control of your ...

This collection encompasses studies exploring the role of gut microbiota, omics analyses, and biomarkers in various disease ...

In patients with Crohn’s disease (CD) of the pouch following ileal-pouch anal anastomosis (IPAA) for medically-refractory ...

With colorectal cancer on the rise in people under 50, researchers at the University of Illinois Urbana-Champaign are looking ...

Cosmo Pharmaceuticals on Friday reported the renewal of its multi-year manufacturing and supply agreement with Takeda (TAK), ...

Patients with inflammatory bowel disease (IBD) have a 48% greater relative risk of developing interstitial lung disease (ILD) ...

NDA for icotrokinra for the treatment of adults and adolescents 12 years of age and older with moderate to severe plaque ...

Palisade Bio, Inc. (($PALI)) announced an update on their ongoing clinical study. Study Overview: Palisade Bio, Inc. has completed a Phase 1 ...

“These results represent a significant milestone for PALI-2108,” said JD Finley, Chief Executive Officer of Palisade Bio. “The early clinical activity, targeted delivery, dose flexibility, the ...

GAAP revenue more than doubled to $22.3 million in Q2 2025 compared to Q2 2024, significantly surpassing the Q2 2025 GAAP revenue estimate of $11.68 million. GAAP earnings per share improved to $(1.34 ...

Key Points GAAP loss per share of $0.55 in Q2 2025 beat analyst estimates by $1.13. GAAP revenue of $5.5 million in Q2 2025 missed expectations by 26%. Advanced key clinical programs, with first U.S.